Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences industry. In today's Pharmaceutical Executive Daily, Jazz Pharmaceuticals agrees to acquire Actio Biosciences, Novo Nordisk, Innate Pharma, and Innovent Biologics strike a trio of new partnerships, and a Veeva executive discusses how agentic AI is surfacing HCP insights that traditional field reporting has historically missed. Concurrent with closing, Actio will spin out a separate company focused on other rare neurological diseases, retaining certain assets and staff while Jazz keeps a minority stake. He describes it as shifting field teams from information distribution toward targeted issue resolution. Thanks for listening to Pharmaceutical Executive Daily.